Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2907 - Genotyping and mRNA profiling reveal actionable targets in biliary tract cancers.

Date

09 Sep 2017

Session

Poster display session

Topics

Translational Research;  Hepatobiliary Cancers

Presenters

Kyriaki Papadopoulou

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

K. Papadopoulou1, S. Murray2, K. Manousou1, I. Tikas1, C. Dervenis1, J. Sgouros1, D. Rontogianni1, S. Lakis1, C. Poulios1, S. Pervana1, G. Lazaridis1, G. Fountzilas1, V. Kotoula1

Author affiliations

  • 1 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 2 Ν/Α, BioPath Innovations SA, Athens/GR
More

Resources

Abstract 2907

Background

Biliary tract cancer (BTC) is a heterogeneous disease of poor prognosis and variable pathogenesis, prompting for the identification of tumor features that may aid in the design of personalized treatments. Herein, we examined genotype and angiogenesis-related features in BTC.

Methods

We applied genotyping (Sanger, qPCR, 101-gene panel NGS) and mRNA relative quantification methods in 84 FFPE BTC (55 gallbladder [GBC], 14 intrahepatic [ICC], 15 extrahepatic [ECC] carcinomas), along with b-catenin immunohistochemistry (IHC).

Results

We identified 541 mutations in 68 (81%) tumors. Six GBC had 17 – 160 mutations, multiple per gene (hypermutated [hm]); non-hm tumors had

Conclusions

We confirmed the presence of different genotypes among GBC, ICC and ECC. Novel findings are the coexistence of PI3K and WNT pathway gene alterations in BTC, their association with angiogenesis, and the hmGBC subtype with HRR gene mutations, which may be considered for new treatment options in this difficult to treat disease.

Clinical trial identification

N/A

Legal entity responsible for the study

Hellenic Cooperative Oncology Group (HeCOG)

Funding

HeCOG

Disclosure

G. Fountzilas: Honoraria: AstraZeneca. Consulting or advisory role: Pfizer, Sanofi, Roche Stock. Ownership: Ariad (immediate family member). All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.